Literature DB >> 26586399

Sodium glycididazole enhances the radiosensitivity of laryngeal cancer cells through downregulation of ATM signaling pathway.

Yue-Can Zeng1, Rui Xing1, Jing Zeng2, Ming Xue3, Feng Chi1, Yan Xin4, Guo-Liang Fan5, Hong-Mei Wang6, Qiong-Yu Duan1, Yu-Nan Sun1, Nan Niu1, Rong Wu7.   

Abstract

The purpose of this study was to evaluate the radiation-enhancing effect of sodium glycididazole, and the corresponding mechanisms of action on laryngeal cancer cells. Two laryngeal cancer cell lines (Hep-2 and UT-SCC-19A) were irradiated with X-rays in the presence or absence of sodium glycididazole. Cell survival, DNA damage and repair, cell apoptosis, cell cycle distribution, expression of proteins related to cell cycle checkpoint, and apoptosis were measured. Significantly increased DNA damages, decreased cells in the G1 phase, arrested cells at G2/M phase, decreased DNA repair protein XRCC1 foci formation, and enhanced cell apoptosis were observed in laryngeal cell lines treated by sodium glycididazole combined with irradiation compared with the irradiation alone. The combined treatment downregulated the protein expressions of ataxia-telangiectasia mutated (ATM), p-ATM, CHK2, and P53 but upregulated the protein expressions of MDM2 and Cdk2. This study indicates that sodium glycididazole enhances the radiosensitivity of laryngeal cancer cells through downregulation of ATM signaling pathway in vitro and in vivo.

Entities:  

Keywords:  ATM signaling pathway; Laryngeal cancer; Radiation-enhancing effect; Sodium glycididazole

Mesh:

Substances:

Year:  2015        PMID: 26586399     DOI: 10.1007/s13277-015-4278-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  28 in total

Review 1.  The interplay between nonhomologous end-joining and cell cycle checkpoint factors in development, genomic stability, and tumorigenesis.

Authors:  D O Ferguson; J M Sekiguchi; K M Frank; Y Gao; N E Sharpless; Y Gu; J Manis; R A DePinho; F W Alt
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2000

Review 2.  The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.

Authors:  Joanne Smith; Lye Mun Tho; Naihan Xu; David A Gillespie
Journal:  Adv Cancer Res       Date:  2010       Impact factor: 6.242

3.  Identification of the PAG1 gene as a novel target of inherent radioresistance in human laryngeal carcinoma cells.

Authors:  Qing Ke; Junbo Wu; Bangchun Ming; Shengming Zhu; Minghua Yu; Yun Wang; Chenghao Hu; Shuangbing Xu; Zhiguo Luo
Journal:  Cancer Biother Radiopharm       Date:  2012-09-20       Impact factor: 3.099

4.  Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line.

Authors:  Wan-ju Kim; Quynh N Vo; Meena Shrivastav; Tamara A Lataxes; Kevin D Brown
Journal:  Oncogene       Date:  2002-05-30       Impact factor: 9.867

5.  [Phase I study of CM-Na combined with concurrent radiochemotherapy for advanced esophageal carcinoma].

Authors:  Ling Cai; Meng-Zhong Liu; Mo-Fa Gu; Hui Liu; Er-Cheng Chen; Yong-Hong Hu; Huan-Xin Lin; Han-Yu Wang; Ying Huang; Qiao-Qiao Li; Nian-Ji Cui; Tie-Hua Rong
Journal:  Ai Zheng       Date:  2005-05

Review 6.  Ataxia-telangiectasia mutated kinase (ATM) as a central regulator of radiation-induced DNA damage response.

Authors:  Ales Tichý; Jirina Vávrová; Jaroslav Pejchal; Martina Rezácová
Journal:  Acta Medica (Hradec Kralove)       Date:  2010

7.  STAT3 inhibitor stattic enhances radiosensitivity in esophageal squamous cell carcinoma.

Authors:  Qu Zhang; Chi Zhang; Jia He; Qing Guo; Desheng Hu; Xi Yang; Jinfeng Wang; Yahui Kang; Ruifang She; Zhongming Wang; Defan Li; Guanhong Huang; Zhaoming Ma; Weidong Mao; Xiaoyi Zhou; Chuangying Xiao; Xinchen Sun; Jianxin Ma
Journal:  Tumour Biol       Date:  2014-12-10

8.  [Phase II clinical trial of sodium glyci-didazole (CM-Na) combined with concurrent radiochemotherapy for advanced esophageal carcinoma].

Authors:  Jie Yang; Meng-Zhong Liu; Ling Cai; Yong-Hong Hu; Hui Liu; Qiao-Qiao Li; Nian-Ji Cui
Journal:  Ai Zheng       Date:  2008-06

9.  Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.

Authors:  Arlene A Forastiere; Qiang Zhang; Randal S Weber; Moshe H Maor; Helmuth Goepfert; Thomas F Pajak; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Wade Thorstad; Henry Wagner; John F Ensley; Jay S Cooper
Journal:  J Clin Oncol       Date:  2012-11-26       Impact factor: 44.544

10.  Molecular mechanisms of ultraviolet radiation-induced DNA damage and repair.

Authors:  Rajesh P Rastogi; Ashok Kumar; Madhu B Tyagi; Rajeshwar P Sinha
Journal:  J Nucleic Acids       Date:  2010-12-16
View more
  5 in total

1.  Preclinical study on hypoxic radiosensitizing effects of glycididazole in comparison with those of doranidazole in vitro and in vivo.

Authors:  Hironobu Yasui; Nobuo Kubota; Junko Nishizumi; Yuri Sakai; Tohru Yamamori; Osamu Inanami
Journal:  Oncol Lett       Date:  2017-11-23       Impact factor: 2.967

2.  miR-30a radiosensitizes non-small cell lung cancer by targeting ATF1 that is involved in the phosphorylation of ATM.

Authors:  Yuyan Guo; Wenze Sun; Tuotuo Gong; Yanlan Chai; Juan Wang; Beina Hui; Yi Li; Liping Song; Ying Gao
Journal:  Oncol Rep       Date:  2017-02-14       Impact factor: 3.906

3.  The Radiosensitization of Sodium Glycididazole on Nasopharyngeal Carcinoma Cells via Enhancing DNA Damage and Promoting Apoptosis.

Authors:  Xiaoli Min; Fangling Huang; Huichao Huang; Shuang Zhao; Guoqiang Wang; Minze Zhou; Zhuchu Chen; Maoyu Li; Yongheng Chen
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

4.  Ataxia-Telangiectasia Mutated (ATM) Protein Signaling Participates in Development of Pulmonary Arterial Hypertension in Rats.

Authors:  Fan Hu; Caijun Liu; Hanmin Liu; Liang Xie; Li Yu
Journal:  Med Sci Monit       Date:  2017-09-12

5.  Enhanced radiosensitizing by sodium glycididazole in a recurrent esophageal carcinoma tumor model.

Authors:  Peipei Wu; Jing Liu; Xiaorong Sun; Xiaolin Li; Ligang Xing; Jinming Yu
Journal:  Oncotarget       Date:  2017-07-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.